Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
  • English
    • 日本語
Evaluate Logo

navigation

  • What We Do
  • Vantage
    • News
    • Analysis
    • Policy & Pricing
    • Data Insights
    • Events
    • Medtech
    • Therapy Areas
    • About Vantage
      • Editorial team
  • Products & Services
    • Consensus Forecasts
    • Pharma
      • EvaluatePharma
      • EvaluatePharma Vision
    • Custom Solutions
    • How We Can Help You
      • Pharma and Biotech
      • Medtech
      • Financial Services
      • Management Consultancies
      • Service Providers
    • Client Success
    • Customer Testimonials
  • Thought Leadership
    • English
    • 日本語
  • About Us
    • Media Centre
      • Press Releases
      • Media Coverage
    • Executive Team
    • Vision & History
  • Careers
    • Current Vacancies
  • Contact Us
  • Sign Up for Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Policy & Pricing
    • Policy & Regulation
    • Pricing
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Chimerix

Thumbnail
January 27, 2017

Upcoming events – Late-stage data from Trevena and Chimerix

August 15, 2016

Therapy focus – Hepatitis B developers try to repeat Gilead’s hep C trick

Vantage logo
January 07, 2016

Wobbles aside, small pharma shares broadly on the up in 2015

Vantage logo
January 04, 2016

Pharma regulatory and development news over Christmas

Vantage logo
October 22, 2014

Bavarian Nordic leaps ahead in Ebola race

Vantage logo
March 20, 2014

Circassia joins the exclusive $100m+ IPO club

Vantage logo
January 06, 2014

Fast times in biotech push IPO count to new highs

Vantage logo
December 17, 2013

Vantage Point – Under pressure to return profits, venture funds raise new money

Vantage logo
July 10, 2013

Floats rise out of the biotech bubble at last

Vantage logo
May 29, 2013

IPO flurry raises valuation gap questions

Vantage logo
February 13, 2013

Product deal values continue to head south in 2012

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

July 31, 2019

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

February 26, 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

View more...

Editor's Picks

Vantage logo
October 22, 2019

Shock revelation sees Biogen erase its aducanumab losses

Vantage logo
October 22, 2019

Vertex’s double cystic fibrosis surprise

Vantage logo
October 23, 2019

Bristol might play a role in front-line lung cancer after all

Vantage logo
October 23, 2019

Bloated on arrival? Biotech's weightiest new issues

Vantage logo
October 14, 2019

Uncovering biopharma’s hidden treasures

Open modal

Evaluate HQ +44-(0)20-7377-0800

Evaluate Americas +1-617-573-9450

Evaluate APAC +81 (0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

Follow Us

© Copyright 2019 Evaluate Ltd.